Skip to main content

Mechanisms · Mechanism of Action

Ibogaine Pharmacokinetics

Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination, including the long noribogaine tail that drives the post-flood telemetry window.

DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team

Quick Answer

What is ibogaine pharmacokinetics in ibogaine pharmacology?

Ibogaine is rapidly absorbed orally, hepatically O-demethylated by CYP2D6 to noribogaine, and distributed broadly (high lipophilicity, large volume of distribution). Parent ibogaine has a plasma half-life of roughly 4-7 hours, but noribogaine has a much longer elimination tail, measurable for days to weeks. CYP2D6 polymorphisms (poor, intermediate, extensive, ultra-rapid metabolizers) substantially affect both peak ibogaine concentrations and the rate of noribogaine formation, which is why MindScape includes pharmacogenomic screening in eligibility workup.

Reviewed by Dr. Arellano, M.D. (May 2026)

Absorption and distribution

Ibogaine is administered orally as the hydrochloride salt (HCl). Oral bioavailability is moderate; peak plasma concentrations occur within 1-3 hours of ingestion.

Both ibogaine and noribogaine are highly lipophilic and accumulate in adipose and other lipid-rich tissues. This accounts for the large apparent volume of distribution and contributes to the long terminal elimination phase observed in pharmacokinetic studies.

CYP2D6 metabolism to noribogaine

Ibogaine is O-demethylated by hepatic CYP2D6 to noribogaine, which is itself pharmacologically active.

CYP2D6 is highly polymorphic. Poor metabolizers (≈ 5-10% of European-ancestry populations) convert ibogaine to noribogaine more slowly, leading to higher and more prolonged ibogaine concentrations. Ultra-rapid metabolizers do the opposite. This is why MindScape includes pharmacogenomic screening in the eligibility workup where indicated.

  • Poor metabolizers: prolonged ibogaine exposure, slower noribogaine generation; adjust dose or defer.
  • Intermediate metabolizers: moderate impact, standard protocol with closer monitoring.
  • Extensive (normal) metabolizers: standard PK profile.
  • Ultra-rapid metabolizers: faster ibogaine clearance, potentially blunted clinical effect.

Elimination: the long noribogaine tail

Parent ibogaine's plasma half-life is ≈ 4-7 hours. Noribogaine's half-life is much longer. Glue et al. (2016) report estimates ranging from 28 to 49 hours after single oral dosing in opioid-dependent patients.

This long noribogaine tail is why MindScape maintains continuous cardiac telemetry for 72-96 hours post-flood dose: it covers the window during which noribogaine concentrations remain pharmacologically active.

Targets

  • CYP2D6
  • Noribogaine
  • Plasma protein binding
  • Adipose distribution

Citations & Reading

  • Glue P, et al. (2016). Clinical Pharmacology in Drug Development, 5(6), 460-468.
  • Mash DC, et al. (2018). Frontiers in Pharmacology, 9, 529.
  • Knuijver T, et al. (2022). Addiction, 117(1), 118-128.

For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.

Related mechanisms

Clinical Calls

Have a question about this mechanism?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation